Cartesian Therapeutics, Inc. Board of Directors

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

Dr. Carsten Brunn Ph.D.

Dr. Carsten Brunn Ph.D.

President, CEO & Director

Dr. Emily English Ph.D.

Dr. Emily English Ph.D.

SVP & Head of Manufacturing

Mr. Matthew Bartholomae J.D.

Mr. Matthew Bartholomae J.D.

General Counsel & Secretary

Dr. Chris Jewell Ph.D.

Dr. Chris Jewell Ph.D.

Chief Scientific Officer

Mr. Blaine T. Davis

Mr. Blaine T. Davis

Chief Financial Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.